Target Audience

Family physicians, specialists and allied health professionals.

Program Access
Listen Now
Program Description

Heart failure with preserved EF (HFpEF) carries substantial morbidity and mortality, yet evidence-based treatments to improve outcomes are sorely lacking. Recently, the FDA made the unusual decision to approve

sacubitril/valsartan for HFpEF despite a neutral trial with this agent. Similarly, while spironolactone’s major trial in HFpEF was not positive, guidelines have endorsed this therapy based on sub-group analyses. This podcast will explore why these decisions were made and whether these treatments should be considered for HFpEF patients.

Learning Objectives:

  • To review current treatment strategies for HFpEF
  • To understand how neutral trials may still influence guidelines and practice


This program is NOT accredited.

Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.

Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio. 

Back To Programs
Available Online

Mar. 19, 2020



Being a part of CCRN has benefits